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Abstract
The GMO Panel was previously not in the position to complete the food/feed safety assessment of
maize 5307 due to an inadequate 28-day toxicity study necessary for an appropriate assessment of
eCry3.1Ab protein. Following a mandate from the European Commission, the GMO Panel assessed a
supplementary 28-day toxicity study in mice on the eCry3.1Ab protein (1,000 mg/kg body weight (bw)
per day) to complement its scientiﬁc opinion on application EFSA-GMO-DE-2011-95 for the placing on
the market of the maize 5307 for food and feed uses, import and processing. The supplementary
28-day toxicity study did not show adverse effects. Taking into account the previous assessment and
the new information, the GMO Panel concludes that maize 5307, as assessed in the scientiﬁc opinion
on application EFSA-GMO-DE-2011-95 (EFSA GMO Panel, 2015) and in the supplementary toxicity
study, is as safe and nutritious as its conventional counterpart in the scope of this application.
© 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
The GMO Panel was previously not in the position to complete the food/feed safety assessment of
maize 5307 due to an inadequate 28-day toxicity study necessary for an appropriate assessment of
eCry3.1Ab protein.
On 23 December 2016, the European Commission requested the GMO Panel to complement its
scientiﬁc opinion on application EFSA-GMO-DE-2011-95 for the placing on the market of the maize
5307 for food and feed uses, import and processing (EFSA GMO Panel, 2015) taking into consideration
a supplementary toxicity study provided by the applicant after the adoption of the EFSA opinion.
The GMO Panel assessed the supplementary 28-day oral repeated dose toxicity study in mice on
the eCry3.1Ab protein at 1,000 mg/kg body weight (bw) per day. The study was conducted in
accordance with OECD TG 407 and with the principles of Good Laboratory Practice. No adverse effects
were observed in this study.
Taking into account the previous assessment and the new information, the GMO Panel concludes
that maize 5307, as assessed in the scientiﬁc opinion on application EFSA-GMO-DE-2011-95 (EFSA
GMO Panel, 2015) and in the supplementary toxicity study, is as safe and nutritious as its conventional
counterpart in the scope of the application.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
On 16 April 2015, the GMO Panel adopted a scientiﬁc opinion on application EFSA-GMO-DE-2011-95
for the placing on the market of maize 5307 for food and feed uses, import and processing under
Regulation (EC) No 1829/2003 (EFSA GMO Panel, 2015). In this scientiﬁc opinion, the GMO
Panel considered that the information available for maize 5307 was not sufﬁcient to reach a ﬁnal
overall conclusion since ‘the EFSA GMO Panel cannot conclude on the safety of the eCry3.1Ab protein’.
This was due to the fact that ‘the 28-day rat oral toxicity study on eCry3.1Ab provided to support the
safety assessment of this newly expressed protein was not considered adequate’.
On 6 May 2015, the European Food Safety Authority (EFSA) received a letter from the applicant
where they disputed the claim that the 28-day toxicity study was inadequate and indicated that such a
study was compliant with applicable OECD protocols and entirely adequate for a proper food/feed risk
assessment by toxicologists. On 19 May 2015, EFSA replied reiterating that the study showed a major
deviation from the applicable OECD protocol TG 407 (2008) leading to the impossibility of deriving a
scientiﬁcally meaningful conclusion on the toxicological proﬁle of maize 5307. Furthermore, in this
letter, EFSA offered to the applicant to consider a post-adoption teleconference to further clarify the
scientiﬁc rationale leading to the conclusions of the scientiﬁc opinion.1
Following the publication of the scientiﬁc opinion on maize 5307, on 1 June 2015, the applicant
requested EFSA a post-adoption teleconference. Following exchanges with the applicant (EFSA to the
applicant on 16 June 2015, 22 June 2015 and 30 June 2015; the applicant to EFSA on 19 June 2015
and 24 June 2015), the meeting was held on 2 July 2015. In this context, EFSA provided clariﬁcations
on the original 28-day study weaknesses; Syngenta acknowledged that the study contained an unusual
deviation from OECD TG 407 (2008) and conﬁrmed that a new 28-day toxicity study in rodents on the
eCry3.1Ab protein would have been provided. This was reiterated in a letter sent to EFSA on 3 July
2015. EFSA provided the applicant a summary of the post-adoption teleconference on 17 July 2015.
On 23 December 2016, the European Commission mandated EFSA to assess a new 28-day toxicity
study on the eCry3.1Ab protein received from the applicant on 8 December 2016, and to complement
its original scientiﬁc opinion on maize 5307 taking into consideration this additional information. EFSA
acknowledged the receipt of the mandate on 23 March 2017.
The GMO Panel asked the applicant clariﬁcations on this supplementary toxicity study on 22 May 2017,
20 October 2017 and 17 November 2017. Following a request by the applicant, on 6 June 2017, EFSA
invited the applicant to a clariﬁcation teleconference regarding EFSA question sent on 22 May 2017
(teleconference held on 12 June 2017). The applicant replied to EFSA on 24 July 2017, 30 October 2017
and 14 December 2017.
In the frame of contract OC/EFSA/UNIT/GMO/2014/02, the contractor performed preparatory work
and delivered a report on the methods applied by the applicant to perform the study.
This statement reports the GMO Panel assessment of this supplementary toxicity study and the
related additional information provided by the applicant following EFSA’s requests.
According to the mandate received from European Commission on 23 December 2016, this
statement complements the EFSA scientiﬁc opinion on maize 5307 (EFSA GMO Panel, 2015), which is
the report requested under Articles 6(6) and 18(6) of Regulation (EC) No 1829/2003 and is part of the
EFSA Overall Opinion in accordance with Articles 6(5) and 18(5) of that Regulation.
2. Data and methodologies
2.1. Data
In delivering this statement, the GMO Panel took into account the supplementary toxicity study
provided by the applicant in the context of this mandate and the EFSA scientiﬁc opinion on application
EFSA-GMO-DE-2011-95 (EFSA GMO Panel, 2015).
2.2. Methodologies
The GMO Panel carried out a scientiﬁc risk assessment of this supplementary toxicity study taking
into account the appropriate principles described in its guidelines for the risk assessment of genetically
modiﬁed (GM) plants and derived food and feed (EFSA GMO Panel, 2011).
1 http://www.efsa.europa.eu/en/supporting/pub/1025e
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3. Assessment
The 28-day oral repeated dose toxicity study in mice on the eCry3.1Ab protein provided in the
context of the current mandate was conducted in accordance with OECD TG 407 (2008) and with the
principles of Good Laboratory Practice.
Groups of Crl:CD1(ICR) mice (12/sex per group; males singly-housed and females caged in pairs;
approximately 6–7 weeks old at study start) were administered by gavage respectively: the eCry3.1Ab
protein (in 0.5% [w/v] carboxymethylcellulose) at a targeted nominal dose of 1,000 mg/kg body
weight (bw) per day (eCry3.1Ab protein group); the vehicle alone (vehicle control group) or bovine
serum albumin (BSA) at a targeted nominal dose of 1,000 mg/kg bw per day (BSA control group).
The test substance used in this 28-day study provided by the applicant contained 80.7% of an
eCry3.1Ab protein produced by a recombinant system (Escherichia coli). This protein was considered
by the GMO Panel to be equivalent to the protein expressed in maize 5307.2
The eCry3.1Ab protein dosing formulation (suspension),3,4 and the BSA protein dosing formulation
were prepared daily. Samples of the eCry3.1Ab protein and BSA dosing formulations were taken on
day 1 and then weekly for concentration analysis (along with vehicle) and for homogeneity analyses.
The GMO Panel noted that stability tests on the test substance (i.e. the lyophilised eCry3.1Ab
protein) were not performed as part of this study. The applicant provided data demonstrating that the
test substance was stable in its function (i.e. insecticidal) in a formulation and in storage conditions as
used in this study.3 The GMO Panel therefore considers that this is not a major deviation compromising
the study.
Feed and water were provided ad libitum. During the treatment period, the animals were checked
twice daily for mortality and clinical signs. Detailed clinical observations were conducted on all animals
once daily after dosing during the treatment period. Body weights were recorded pretreatment
(week 1) and then weekly; body weight gains were calculated relative to test day 1. Feed consumption
was determined weekly.
At the end of the treatment period, blood samples were taken and haematological and clinical
chemistry analyses were performed. All animals were sacriﬁced and underwent a detailed necropsy
examination with selected organs weighed. Organs and tissues from all animals were collected and
subjected to a comprehensive histopathological examination. A pathology peer review was conducted.
For all continuous endpoints, mean and standard deviation were calculated per group (males and
females combined); in addition, mean, standard deviation, median, minimum and maximum, and lower
and upper quartiles were reported for each sex.
In the frame of a preliminary analysis, a signiﬁcant cage effect was noted in socially housed
females for a few endpoints5; these effects were either related to isolated endpoints or to endpoints
derived from others which did not show a signiﬁcant cage effect. Therefore, the analysis of data from
individual animals is considered appropriate.
The eCry3.1Ab protein group was statistically compared to the BSA control group. The latter was also
compared to the vehicle control group in order to assess potential effects of the higher protein intake.6
Furthermore, the eCry3.1Ab protein group was statistically compared to the vehicle control group.
For all the continuous parameters, a two-sided multi-way analysis of variance (ANOVA) at the 5%
signiﬁcance level was conducted for the two sexes combined (factors: sex, block-within-sex,7 three
level treatment, i.e. test substance, vehicle, and BSA, and the two-way interaction between sex and
treatment in order to account for potential sex–dose interactions). A two-way ANOVA (factor: block
and treatment) separately for each sex was performed when needed.8 The data were explored
2 EFSA GMO Panel, 2015 and Additional information 24/7/2017 and 31/10/2017.
3 Additional information 31/10/2017.
4 The purity of the test substance was taken into account in the formulation.
5 Relative organ weight: thymus; clinical chemistry: albumin/globulin ratio, globulin, glucose, urea, alkaline phosphatase,
triglycerides; haematology: mean corpuscular haemoglobin, mean corpuscular volume, red blood cell distribution width.
6 With respect to body weight, including cumulative body weight gain, feed consumption, feed utilisation, haematology and
clinical chemistry, organ weights (absolute and relative to terminal body weight).
7 When an unbalanced occurrence of missing data between sexes was observed (bile acid, calcium, chloride, potassium and
sodium) a pooled model without the block-within-sex term was used.
8 Sex-speciﬁc organ weights (relative and absolute, in the latter the terminal body weight was added to the model as a
covariate); parameters showing unequal variation across the sexes (glucose, triglycerides, eosinophil count and reticulocyte
count). In order to take into account the social housing, in females the cage was used as the experimental unit in the model
for food consumption and food utilisation. Furthermore, males and females are analysed separately if a signiﬁcant interaction
term (Sex*Dose) was identiﬁed in the pooled analysis.
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graphically for outliers and no remarkable deviations were identiﬁed. Therefore, no outliers were
excluded from the analysis. p values for the ﬁxed effect treatments were presented and the estimated
differences among pairwise comparisons were also reported. In addition, estimated means and
conﬁdence intervals for all endpoints were converted from the scale of their natural units (e.g. mg/dL)
to standardised effect size (i.e. normalised to standard deviation).
The few statistically signiﬁcant differences between the BSA and vehicle control groups were
considered by the GMO Panel to be within normal biological variability. Therefore, both these groups
were considered suitable to be used as controls for the comparison and evaluation of data from the
eCry3.1Ab protein group.
The results of the dose conﬁrmation analyses revealed that the measured concentration for
eCry3.1Ab and BSA protein in 0.5% carboxymethylcellulose were within the acceptance criteria of
 20% (–10.7–10.0%) of their theoretical concentrations respectively, based on nominal dosing
suspensions at 100 mg/mL. The results of the homogeneity analyses indicated that the preparations
were homogeneously mixed.
No mortality occurred during the treatment period. The GMO Panel considered that the isolated
clinical ﬁndings observed in the eCry3.1Ab protein group were incidental and not related to the test
substance.
Compared to the BSA control group, feed utilisation was statistically signiﬁcantly lower in males in
week 3, higher in males in week 4 and lower in females in week 2 of the study. There were no
differences in the mean overall feed consumption throughout the study nor in body weight and body
weight gain. The ﬂuctuations in feed utilisation are therefore considered not related to the test
substance.
A statistically signiﬁcantly lower absolute liver weight was seen in animals given the test substance
as compared to BSA control group. This difference was considered of no toxicological relevance since
the relative liver weight was unchanged.
A statistically signiﬁcantly lower glucose level was noted in males given the eCry3.1Ab protein
(10.66  1.151 mmol/L) as compared to BSA controls (12.23  1.352 mmol/L); this difference was
not considered to be adverse.
Macroscopic examinations at necropsy revealed no gross pathological ﬁndings related to the
treatment with the eCry3.1Ab protein. Microscopic examinations of selected organs and tissues
identiﬁed no test substance-related differences in the incidences and severity of the histopathological
ﬁndings between the groups.
The GMO Panel noted the following deviations from OECD TG 407 requirements: coagulation
analysis, functional observational battery and locomotor activity tests were not performed.
Regarding the lack of the coagulation analysis, the GMO Panel considered that the integrated
assessment of related parameters (e.g. no difference in the platelet count between animals given the
eCry3.1Ab protein and those given BSA, or in the spleen and bone marrow histopathology between
groups) indicates that an effect on coagulation parameters is unlikely. The GMO Panel therefore
concludes that this is not a major deviation compromising the safety assessment of the eCry3.1Ab
protein.
Regarding the lack of functional observational battery and locomotor activity tests (tests performed
to identify potential neurotoxicity of a test substance), the GMO Panel used a weight of evidence
approach to evaluate potential neurotoxic effects of the eCry3.1Ab protein: (1) in this 28-day study, no
test substance-related ﬁndings were, according to the study report, noted in the detailed clinical
examinations (performed daily on individual animals outside the cage); (2) no test substance-related
effects were seen in an acute oral toxicity study in mice given 1720 mg eCry3.1Ab protein/kg bw; (3)
no similarity of the eCry3.1Ab protein to known neurotoxicants was identiﬁed in bioinformatics analysis
(EFSA GMO Panel, 2015); (4) according to current knowledge, there is no indication of neurotoxicity
for Cry proteins (e.g. EFSA GMO Panel, 2017a,b; 2016a,b,c). The GMO Panel therefore considers that
the lack of functional observational battery and locomotor activity tests is not a major deviation
compromising the safety assessment of the eCry3.1Ab protein.
The GMO Panel concludes that no adverse effects were observed in this 28-day mouse toxicity
study on eCry3.1Ab protein (1,000 mg/kg bw per day).
4. Conclusions
The 28-day toxicity study on eCry3.1Ab protein assessed by the GMO Panel did not show adverse
effects. Taking into account the previous assessment and the new information, the GMO
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Panel concludes that maize 5307, as assessed in the scientiﬁc opinion on application EFSA-GMO-DE-
2011-95 and in the supplementary toxicity study, is as safe and nutritious as its conventional
counterpart in the scope of this application.
Documentation provided to EFSA
1) Letter from the applicant to EFSA dated 5 May 2015 (received on 6 May 2015) with
comments regarding the Scientiﬁc opinion of the EFSA GMO Panel on maize 5307
(application EFSA-GMO-DE-2011-95).
2) Letter from EFSA to the applicant dated 19 May 2015 replying to the comments on
application EFSA-GMO-DE-2011-95 and inviting the applicant to a post-adoption tele-
conference following the EFSA’s Catalogue of support initiatives during the life-cycle of
applications for regulated products.1
3) Letter from the applicant to EFSA dated 1 June 2015 requesting a post-adoption
teleconference.
4) Letter from EFSA to applicant dated 16 June 2015 inviting the applicant to a post-adoption
teleconference to be held on 2 July 2015 including a draft agenda.
5) E-mail from the applicant to EFSA dated 19 June 2015 accepting the EFSA invitation to a
post-adoption teleconference to be held on 2 July 2015.
6) E-mail from EFSA to applicant dated 22 June 2015 inviting the applicant to provide a list of
items for discussion for the post adoption teleconference to be held on 2 July 2015.
7) Letter from the applicant to EFSA dated 24 June 2015 providing items for discussion the
post adoption teleconference to be held on 2 July 2015.
8) Letter from EFSA to applicant dated 30 June 2015 submitting the ofﬁcial invitation letter to
the post adoption teleconference to be held on 2 July 2015.
9) Letter from EFSA to applicant dated 30 June 2015 submitting the agenda of the post
adoption teleconference on 2 July 2015.
10) Letter from the applicant to EFSA dated 3 July 2015 providing a summary of the discussion the
post adoption teleconference on 2 July 2015 and committing to conduct a new 28-day study.
11) Letter from EFSA to the applicant dated 17 July 2015 summarising the outcome of the
clariﬁcation post-adoption teleconference.
12) Mandate from EC to EFSA received on 23 December 2016, for the assessment of additional
information related to the application for authorisation of food and feed containing,
consisting and produced from genetically modiﬁed maize 5307 (application EFSA-GMO-DE-
2011-95).
13) Acknowledgment letter from EFSA to EC sent on 23 March 2017.
14) Letter from EFSA to the applicant dated 22 May 2017 requesting additional information on
maize 5307.
15) Letter from EFSA to the applicant dated 6 June 2017 calling the applicant for a clariﬁcation
teleconference.
16) Email from EFSA to applicant dated 19 June 2017 summarising the conclusions of the post-
adoption teleconference held on 12 June 2017.
17) Letter from the applicant to EFSA received on 24 July 2017 providing additional information
requested.
18) Letter from EFSA to the applicant dated 20 October 2017 requesting additional information
on maize 5307.
19) Letter from the applicant to EFSA received on 30 October 2017 providing additional
information requested.
20) Letter from EFSA to the applicant dated 17 November 2017 requesting additional
information on maize 5307.
21) Letter from the applicant to EFSA received on 14 December 2017 providing additional
information requested.
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ANOVA analysis of variance
BSA bovine serum albumin
bw body weight
GM genetically modiﬁed
GMO Genetically Modiﬁed Organism
OECD Organisation for Economic Co-operation and Development
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